Claudio Andres Bravo Carrillo, MD
Advanced Heart Failure and Transplant Cardiology · San Francisco
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 12
- 2 carriers
- Offices
- 3
- Since medical school
- 18 years
- Graduated 2008
Offices
3 locations · Regents of the University of California · UCSF Medical Group Business Services · University of California San Francisco
Hospitals listed: Medical City Dallas · UCSF Medical Center. That is not proof they admit you there this week.
Plans that list them
12 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Carrillo’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
12 of 12 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
State licence records
2 licences
- Texas U6120Physician License · since 2023 · expires 2026-08-31Delinquent - Incomplete RegistrationNo board action on this licenceCheck it with the state
- Washington MD.MD.61040173Physician And Surgeon License · since 2020 · expires 2024-11-26ExpiredNo board action on this licenceCheck it with the state
We check Colorado, Delaware, Florida, Illinois, Maryland, New Jersey, New York, Tennessee, Texas, Virginia, Washington, plus California above. A state that is not in this list has not been checked, which is not the same as clear.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Medical City Dallas HospitalDallas, TXAcute Care Hospital · Proprietary · Has an emergency department · Birthing-friendlyPart of HCA Healthcare, which runs 185 hospitals in 19 statesPatients rate it 2 of 5 · 66% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — CMS Medicare PSI 90: Patient safety and adverse events composite: 0.69 (0.45 to 0.93), Jul 2022 – Jun 2024Better than the national rate — Postoperative sepsis rate: 2.29 (0 to 4.92) · 1,684 cases, Jul 2022 – Jun 2024Better than the national rate — Clostridium Difficile (C.Diff): 0.41, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.423, Oct 2024 – Sep 2025
- UCSF Medical CenterSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of University of California Health, which runs 12 hospitalsHome of UCSF Helen Diller Family Comprehensive Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 81% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 4.9 (3.79 to 6.02) · 7,590 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 12.8 (11.3 to 14.4) · 2,019 cases, Jan 2024 – Dec 2024Better than the national rate — Death rate among surgical inpatients with serious treatable complications: 139.4 (110.22 to 168.58) · 452 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.622, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.626, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.491, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.8 (0.7 to 1) · 2,336 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Medical City Dallas Hospital
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 2 better, 6 the same, 0 worse of 8 measures. Readmissions: 0 better, 9 the same, 2 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.69 (0.45 to 0.93) | Better | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 2.29 (0 to 4.92) · 1,684 cases | Better | Jul 2022 – Jun 2024 |
| Clostridium Difficile (C.Diff)Infections | 0.41 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.423 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.7 (0 to 1.6) · 2,078 cases | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 161.11 (114.97 to 207.25) · 126 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2 · 84 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 11 · 97 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 13.9 · 94 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10.7 · 372 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 17.2 · 385 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 11.2 · 255 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.5 · 3,930 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.17 (0 to 0.36) · 8,773 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.19 (0.01 to 0.38) · 9,333 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.41 (0.67 to 4.15) · 2,754 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.15 (0 to 2.59) · 1,521 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.21 (0 to 2.45) · 2,599 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 12.1 (7.79 to 16.42) · 1,757 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.48 (0.08 to 2.88) · 990 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.1 (0 to 0.65) · 7,357 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 74 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.68 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.767 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.879 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.163 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.1 · 190 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.3 · 699 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 14.4 · 126 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -15.8 · 452 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 6 · 413 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.7 · 632 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.5 (3.4 to 8.9) · 41 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.9 (7.4 to 16.1) · 41 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 7.4 · 73 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.5 · 96 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 21 · 171 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 14 (10.4 to 19) · 244 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.1 (0.8 to 1.4) · 515 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,291 patients answered, 17% of those asked)
| Cleanliness | 3 |
| Nurse communication | 2 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 2 |
| Overall hospital rating | 2 |
| Quietness | 4 |
| Recommend hospital | 3 |
| Room was "always" clean | 67% |
| Nurses "always" communicated well | 71% |
| Doctors "always" communicated well | 74% |
| Staff "always" explained | 54% |
| Yes, staff "did" give patients this information | 80% |
| Yes, staff "did" give patients information about help after discharge | 80% |
| Doctors "always" explained things so they could understand | 68% |
| Doctors "always" listened carefully | 72% |
| Doctors "always" treated them with courtesy and respect | 81% |
| Patients who gave a rating of "9" or "10" (high) | 65% |
| Staff "always" explained new medications | 67% |
| Nurses "always" explained things so they could understand | 66% |
| Nurses "always" listened carefully | 67% |
| Nurses "always" treated them with courtesy and respect | 78% |
| "Always" quiet at night | 64% |
| "YES", patients would definitely recommend the hospital | 66% |
| Staff "always" explained possible side effects | 41% |
| Yes, staff "did" give patients information about possible symptoms | 81% |
See every measure and the patient survey for UCSF Medical Center
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 3 better, 5 the same, 3 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.9 (3.79 to 6.02) · 7,590 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.8 (11.3 to 14.4) · 2,019 cases | Worse | Jan 2024 – Dec 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 139.4 (110.22 to 168.58) · 452 cases | Better | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.622 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.626 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.491 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.7 to 1) · 2,336 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.24 (0.58 to 1.9) · 4,689 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.05 (0.89 to 1.2) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.9 · 89 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.5 · 85 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.1 · 132 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.6 · 454 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 618 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 380 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.7 · 5,000 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.22 (0.06 to 0.38) · 15,965 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.05 to 0.35) · 17,859 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.85 (0 to 1.83) · 4,184 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2 (1.1 to 2.9) · 6,516 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.35 (4.49 to 10.21) · 3,989 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5 (3.22 to 6.77) · 4,087 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.95 (0.74 to 3.15) · 2,034 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.95 (0.63 to 1.28) · 15,431 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 399 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.899 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.689 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.224 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16 · 156 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20 · 564 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 60.3 · 160 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -9.7 · 550 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 44.1 · 660 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.8 · 667 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (4.8 to 6.7) · 2,019 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6 · 421 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.5 · 53 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20 · 107 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.9 (11.3 to 17.1) · 3,247 cases | No different | Jan 2022 – Dec 2024 |
What patients said (3,181 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 71% |
| Nurses "always" communicated well | 80% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 78% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 50% |
| "YES", patients would definitely recommend the hospital | 81% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$34,131
Medicare paid this office $34,131 for 73 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Critical care, first 30-74 minutes | 15 | $13,383 | $174 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 23 | $9,026 | $97 |
| Long return visit (40+ min) | 50 | $8,573 | $113 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 15 | $2,031 | $135 |
Who their Medicare patients are
73 Original Medicare patients in 2024. Average age 68 · Women 29% · Health risk score 3.61. Sicker patients than 9 in 10 peers; the typical advanced heart failure and transplant cardiology clinician is at 2.53.
Conditions among them: High blood pressure 75% · Coronary heart disease 75% · Heart failure 75% · Chronic kidney disease 75% · Diabetes 68% · Atrial fibrillation 40% · Depression 33% · COPD 23% · Stroke 23% · Cancer 16%.
The office billed $82,681, Medicare allowed $42,484 and paid $34,131; for 271 services of 8 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 73 | 271 | 68 | 3.61 | $82,681 | $34,131 |
| 2023 | 259 | 647 | 70 | 2.68 | $186,298 | $49,844 |
| 2022 | 432 | 855 | 71 | 2.47 | $196,511 | $57,566 |
| 2021 | 263 | 549 | 69 | 2.48 | $152,013 | $46,755 |
| 2020 | 59 | 211 | 65 | 3.41 | $73,470 | $21,215 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 10 services
| Critical care, first 30-74 minutes | 20 | $9,752 | $181 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 31 | $9,591 | $98 |
| Biopsy of heart muscle | 25 | $8,284 | $188 |
| Long return visit (40+ min) | 47 | $7,224 | $98 |
| Critical care, each additional 30 minutes | 16 | $4,081 | $91 |
| Insertion of tube in right heart chambers for measurement | 25 | $2,382 | $54 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 17 | $2,099 | $68 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 122 | $1,018 | $7 |
| Hospital discharge day management, 30 minutes or less | 13 | $908 | $70 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 14 | $104 | $7 |
2022: 9 services
| Critical care, first 30-74 minutes | 27 | $18,865 | $181 |
| Long return visit (40+ min) | 53 | $11,875 | $122 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 28 | $9,318 | $85 |
| Biopsy of heart muscle | 22 | $4,834 | $186 |
| Critical care, each additional 30 minutes | 14 | $4,148 | $88 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 256 | $2,150 | $7 |
| Insertion of tube in right heart chambers for measurement | 24 | $1,824 | $63 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 11 | $1,650 | $61 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 53 | $331 | $6 |
2021: 9 services
| Long return visit (40+ min) | 65 | $14,470 | $114 |
| Critical care, first 30-74 minutes | 23 | $12,857 | $186 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 31 | $6,856 | $85 |
| New patient visit (60+ min) | 26 | $3,902 | $150 |
| Biopsy of heart muscle | 19 | $3,215 | $169 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 11 | $1,473 | $61 |
| Insertion of tube in right heart chambers for measurement | 19 | $998 | $53 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 106 | $835 | $7 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 22 | $146 | $7 |
2020: 3 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 22 | $6,217 | $90 |
| Biopsy of heart muscle | 15 | $3,506 | $195 |
| Insertion of tube in right heart chambers for measurement | 15 | $1,030 | $57 |
Medicaid work
$913 in 2023
Medicaid paid $913 for 197 billed services this clinician did in 2023, up to 49 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 184 | $694 |
| Right heart catheterization including measurement(s) of oxygen saturation and cardiac output, when performed | 13 | $219 |
| 2023 | 197 | 2 | 49 | $913 |
| 2022 | 257 | 1 | 66 | $947 |
| 2021 | 168 | 3 | 33 | $3,475 |
See the largest Medicaid services in earlier years
2022
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 257 | $947 |
2021
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 38 | $1,647 |
| Long return visit (40+ min) | 28 | $1,502 |
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 102 | $325 |
Drugs they prescribed that Part D paid
$64,104
Pharmacies billed $64,104 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 242) in 2024. At or below the middle of the specialty; the typical advanced heart failure and transplant cardiology clinician is at 0%.
177 generic and 53 brand-name prescriptions · $64,104 in drug cost · 14 antibiotic prescriptions.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Jardiance | 24 | $23,247 | $969 |
| Entresto | 20 | $21,768 | $1,088 |
| Westab Plus | 11 | $325 | $30 |
| Metoprolol | 14 | $195 | $14 |
| Atorvastatin | 17 | $189 | $11 |
See all 8 drugs
| Jardiance | 24 | $23,247 | $969 |
| Entresto | 20 | $21,768 | $1,088 |
| Westab Plus | 11 | $325 | $30 |
| Metoprolol | 14 | $195 | $14 |
| Atorvastatin | 17 | $189 | $11 |
| Pravastatin | 15 | $83 | $6 |
| Alendronate | 15 | $68 | $5 |
| Sulfamethoxazole-Trimethoprim | 13 | $46 | $4 |
Year by year
| 2024 | 242 | 63 | 0% (0) | 22% | $64,104 |
| 2023 | 1,084 | 93 | 0% (0) | 20% | $233,857 |
| 2022 | 825 | 77 | None | 19% | $146,681 |
| 2021 | 620 | 71 | 0% (0) | None | $104,544 |
| 2020 | 128 | 19 | 0% (0) | 25% | $27,995 |
| 2019 | 257 | 31 | 0% (0) | None | $23,035 |
| 2018 | 167 | 33 | 0% (0) | 13% | $9,527 |
| 2017 | 221 | 44 | None | 10% | $7,399 |
| 2016 | 673 | 89 | None | None | $62,531 |
| 2015 | 831 | 116 | 3% (25) | 27% | $81,895 |
| 2014 | 647 | 85 | 4% (28) | None | $37,703 |
| 2013 | 88 | 17 | None | 23% | $6,105 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 27 drugs
| Entresto | 82 | $87,922 | $1,072 |
| Jardiance | 58 | $64,799 | $1,117 |
| Eliquis | 37 | $38,634 | $1,044 |
| Dapsone | 23 | $2,461 | $107 |
| Torsemide | 42 | $1,960 | $47 |
| Metoprolol | 88 | $1,957 | $22 |
| Atorvastatin | 71 | $1,469 | $21 |
| Potassium Chloride | 19 | $1,210 | $64 |
| Spironolactone | 91 | $1,173 | $13 |
| Eplerenone | 12 | $751 | $63 |
| Pravastatin | 48 | $725 | $15 |
| Pantoprazole | 50 | $697 | $14 |
| Isosorbide Mononitrate Er | 16 | $680 | $43 |
| Westab Plus | 13 | $504 | $39 |
| Ezetimibe | 16 | $408 | $25 |
| Alendronate | 47 | $397 | $8 |
| Chlorthalidone | 12 | $351 | $29 |
| Carvedilol | 21 | $327 | $16 |
| Sulfamethoxazole-Trimethoprim | 36 | $299 | $8 |
| Clopidogrel | 14 | $286 | $20 |
| Losartan | 23 | $274 | $12 |
| Furosemide | 28 | $246 | $9 |
| Digoxin | 13 | $242 | $19 |
| Amlodipine Besylate | 29 | $179 | $6 |
| Levothyroxine | 13 | $150 | $12 |
| Lisinopril | 16 | $114 | $7 |
| Trazodone | 13 | $89 | $7 |
2022: 22 drugs
| Entresto | 74 | $73,005 | $987 |
| Eliquis | 16 | $21,160 | $1,322 |
| Repatha Sureclick | 11 | $6,035 | $549 |
| Metoprolol | 72 | $2,260 | $31 |
| Eplerenone | 11 | $2,038 | $185 |
| Potassium Chloride | 22 | $1,593 | $72 |
| Spironolactone | 82 | $1,257 | $15 |
| Torsemide | 28 | $905 | $32 |
| Atorvastatin | 43 | $824 | $19 |
| Pantoprazole | 43 | $650 | $15 |
| Sulfamethoxazole-Trimethoprim | 42 | $523 | $12 |
| Isosorbide Mononitrate Er | 16 | $520 | $32 |
| Pravastatin | 32 | $439 | $14 |
| Losartan | 17 | $347 | $20 |
| Alendronate | 27 | $245 | $9 |
| Levothyroxine | 29 | $232 | $8 |
| Carvedilol | 15 | $230 | $15 |
| Clopidogrel | 12 | $206 | $17 |
| Furosemide | 15 | $189 | $13 |
| Prenatal Vitamin Plus Low Iron | 13 | $166 | $13 |
| Amlodipine Besylate | 16 | $73 | $5 |
| Lisinopril | 18 | $44 | $2 |
2021: 17 drugs
| Entresto | 65 | $50,471 | $776 |
| Eliquis | 18 | $15,765 | $876 |
| Jardiance | 13 | $9,552 | $735 |
| Metoprolol | 54 | $1,655 | $31 |
| Torsemide | 40 | $1,202 | $30 |
| Spironolactone | 75 | $1,072 | $14 |
| Potassium Chloride | 16 | $644 | $40 |
| Atorvastatin | 35 | $501 | $14 |
| Losartan | 15 | $357 | $24 |
| Pantoprazole | 15 | $228 | $15 |
| Clopidogrel | 11 | $190 | $17 |
| Carvedilol | 18 | $158 | $9 |
| Furosemide | 17 | $126 | $7 |
| Lisinopril | 17 | $103 | $6 |
| Alendronate | 11 | $93 | $8 |
| Sulfamethoxazole-Trimethoprim | 15 | $78 | $5 |
| Amlodipine Besylate | 13 | $57 | $4 |
2020: 4 drugs
| Entresto | 17 | $17,994 | $1,058 |
| Torsemide | 22 | $499 | $23 |
| Carvedilol | 11 | $125 | $11 |
| Atorvastatin | 11 | $65 | $6 |
2019: 9 drugs
| Metoprolol | 31 | $857 | $28 |
| Atorvastatin | 38 | $725 | $19 |
| Torsemide | 18 | $297 | $17 |
| Nifedipine Er | 11 | $215 | $20 |
| Clopidogrel | 13 | $204 | $16 |
| Isosorbide Mononitrate Er | 11 | $121 | $11 |
| Losartan | 21 | $106 | $5 |
| Spironolactone | 11 | $63 | $6 |
| Lisinopril | 15 | $59 | $4 |
2018: 4 drugs
| Metoprolol | 15 | $358 | $24 |
| Atorvastatin | 33 | $354 | $11 |
| Losartan | 25 | $97 | $4 |
| Furosemide | 12 | $36 | $3 |
2017: 6 drugs
| Metoprolol | 35 | $1,128 | $32 |
| Chlorthalidone | 21 | $830 | $40 |
| Atorvastatin | 30 | $523 | $17 |
| Amlodipine Besylate | 17 | $138 | $8 |
| Lisinopril | 12 | $88 | $7 |
| Furosemide | 11 | $42 | $4 |
2016: 16 drugs
| Januvia | 23 | $12,108 | $526 |
| Lantus Solostar | 12 | $4,526 | $377 |
| Nasonex | 11 | $2,665 | $242 |
| Atorvastatin | 67 | $1,028 | $15 |
| Chlorthalidone | 21 | $814 | $39 |
| Ventolin Hfa | 12 | $624 | $52 |
| Levothyroxine | 23 | $434 | $19 |
| Metoprolol | 11 | $347 | $32 |
| Pantoprazole | 34 | $290 | $9 |
| Amlodipine Besylate | 41 | $269 | $7 |
| Metformin | 40 | $253 | $6 |
| Lisinopril | 41 | $169 | $4 |
| Losartan | 11 | $77 | $7 |
| Carvedilol | 13 | $68 | $5 |
| Glipizide | 15 | $60 | $4 |
| Alendronate | 11 | $30 | $3 |
2015: 21 drugs
| Januvia | 23 | $10,284 | $447 |
| Lyrica | 15 | $5,213 | $348 |
| Lantus Solostar | 11 | $4,164 | $379 |
| Xarelto | 12 | $3,989 | $332 |
| Atrovent Hfa | 14 | $3,667 | $262 |
| Atorvastatin | 76 | $1,376 | $18 |
| Levothyroxine | 29 | $589 | $20 |
| Metformin | 40 | $218 | $5 |
| Gabapentin | 14 | $215 | $15 |
| Warfarin | 14 | $202 | $14 |
| Pantoprazole | 24 | $188 | $8 |
| Cyclobenzaprine | 15 | $175 | $12 |
| Lisinopril | 42 | $157 | $4 |
| Amlodipine Besylate | 37 | $127 | $3 |
| Tramadol | 23 | $124 | $5 |
| Trazodone | 17 | $120 | $7 |
| Ranitidine | 17 | $102 | $6 |
| Metoprolol | 20 | $69 | $3 |
| Citalopram Hbr | 11 | $57 | $5 |
| Prednisone | 11 | $51 | $5 |
| Meloxicam | 13 | $44 | $3 |
2014: 18 drugs
| Lansoprazole | 12 | $804 | $67 |
| Atorvastatin | 38 | $429 | $11 |
| Cyclobenzaprine | 21 | $368 | $18 |
| Isosorbide Dinitrate | 13 | $325 | $25 |
| Hydralazine | 24 | $221 | $9 |
| Pantoprazole | 23 | $192 | $8 |
| Spironolactone | 17 | $148 | $9 |
| Clopidogrel | 18 | $137 | $8 |
| Lisinopril | 23 | $125 | $5 |
| Carvedilol | 20 | $106 | $5 |
| Metformin | 15 | $105 | $7 |
| Furosemide | 18 | $95 | $5 |
| Tramadol | 23 | $87 | $4 |
| Enalapril Maleate | 11 | $86 | $8 |
| Metoprolol | 11 | $81 | $7 |
| Prednisone | 13 | $72 | $6 |
| Amlodipine Besylate | 18 | $64 | $4 |
| Glipizide | 12 | $45 | $4 |
Money from drug and device companies
$481 in 2025
| 2025 | 8 | 16 | None | $481 |
| 2024 | 16 | 47 | None | $2,050 |
| 2023 | 1 | 3 | None | $299 |
| 2022 | 2 | 2 | None | $333 |
| 2019 | 3 | 5 | None | $722 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Abiomed | None | $211 | 6 payments
|
| Kestra Medical Technology Services | Assure Wcd | $66 | 2 payments
|
| E.R. Squibb & Sons L.L.C. | Camzyos | $52 | 2 payments
|
| Abbott Laboratories | Thoratec Heartmate 3 Lvas Implant Kit | $49 | 2 payments
|
| AtriCure | Synergy Ablation System | $31 | 1 payment
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $28 | 1 payment
|
See all 16 published payments
| Abbott Laboratories | Meals · 2025-12-14 | Thoratec Heartmate 3 Lvas Implant Kit | $25 |
| Abiomed | Meals · 2025-11-14 | None | $45 |
| Abiomed | Meals · 2025-07-25 | None | $54 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Meals · 2025-07-17 | Lifevest | $28 |
| AtriCure | Meals · 2025-07-17 | Synergy Ablation System | $31 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-07-16 | Camzyos | $25 |
| Abiomed | Meals · 2025-07-03 | None | $18 |
| Kestra Medical Technology Services | Meals · 2025-05-29 | Assure Wcd | $42 |
| Kestra Medical Technology Services | Meals · 2025-05-14 | Assure Wcd | $24 |
| Abbott Laboratories | Meals · 2025-04-11 | Thoratec Heartmate 3 Lvas Implant Kit | $24 |
| Abiomed | Meals · 2025-03-25 | None | $37 |
| Abiomed | Meals · 2025-02-19 | None | $25 |
| Novo Nordisk | Meals · 2025-02-10 | Ozempic | $24 |
| Abiomed | Meals · 2025-01-30 | None | $32 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-01-30 | Camzyos | $27 |
| Novartis Pharmaceuticals | Meals · 2025-01-27 | Leqvio | $20 |
See earlier years (2024, 2023, 2022, 2019)
2024: $2,050
| Abbott Laboratories | Thoratec Heartmate 3 Lvas Implant Kit | $912 | 9 payments
|
| Abiomed | Impella | $421 | 13 payments
|
| Paragonix Technologies | Sherpapak | $152 | 1 payment
|
| Atricure | Synergy Ablation System | $91 | 2 payments
|
| E.R. Squibb & Sons L.L.C. | Camzyos | $64 | 3 payments
|
| Novartis Pharmaceuticals | Leqvio | $61 | 3 payments
|
| Scpharmaceuticals | Furoscix | $58 | 3 payments
|
| Kamada | Cytogam | $51 | 3 payments
|
| Novo Nordisk | Ozempic | $42 | 2 payments
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $37 | 2 payments
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $33 | 1 payment
|
| Edwards Lifesciences | Inspiris Resilia Aortic Valve | $30 | 1 payment
|
| Boston Scientific | Latitude Communicator Power Supply | $28 | 1 payment
|
| Pfizer | Vyndaqel | $26 | 1 payment
|
| Amgen | Repatha | $22 | 1 payment
|
| Baxter Healthcare | Hillrom - Carnation Ambulatory Monitor | $20 | 1 payment
|
2023: $299
| Abbott Laboratories | Thoratec Heartmate 3 Lvas Implant Kit | $299 | 3 payments
|
2022: $333
| Abbott Laboratories | Thoratec Heartmate 3 Lvas Implant Kit | $195 | 1 payment
|
| Abiomed | Impella | $138 | 1 payment
|
2019: $722
| Medtronic Vascular | None | $663 | 2 payments
|
| Amgen | Repatha | $44 | 2 payments
|
| AstraZeneca Pharmaceuticals LP | Brilinta | $15 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 94.9 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1003254186
- Licence
- TX U6120, WA MD61040173Texas U6120: Delinquent - Incomplete RegistrationWashington MD.MD.61040173: Expired
- Group
- Regents of the University of California · UCSF Medical Group Business Services · University of California San Francisco
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RA0001X (207RA0001X); Cardiology (207RC0000X)
- Mailing address
- 535 Mission Bay Blvd S, San Francisco, CA, 94143
- NPI first listed
- 2013-06-11
- NPI last updated
- 2025-12-03
- NPI record certified
- 2025-12-03
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 535 Mission Bay Blvd S, San Francisco, CA, 94143